Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the Canadian GRACE Experience)-Reference-Cited by-同舟云学术

Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the Canadian GRACE Experience)

Published:2012-05 Issue:10 Volume:109 Page:1418-1424
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Elbarouni Basem,Banihashemi S. Behnam,Yan Raymond T.,Welsh Robert C.,Kornder Jan M.,Wong Graham C.,Anderson Frederick A.,Spencer Frederick A.,Grondin François R.,Goodman Shaun G.,Yan Andrew T.

Funder

Heart and Stroke Foundation of Canada

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference25 articles.

1. Association between lipid testing and statin therapy in acute myocardial infarction patients;Ko;Am Heart J,2005

2. Lipid management in patients with unstable angina pectoris and non–ST-segment elevation acute myocardial infarction (from CRUSADE);Foody;Am J Cardiol,2005

3. Statin use after acute myocardial infarction: a nationwide study in Denmark;Rasmussen;Br J Clin Pharmacol,2005

4. Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to 2006;Fonarow;Am Heart J,2009

5. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome;Yan;Am Heart J,2007

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis;Clínica e Investigación en Arteriosclerosis (English Edition);2023-07

2. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: A systematic review and meta-analysis;Clínica e Investigación en Arteriosclerosis;2022-12

3. Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome;Circulation: Cardiovascular Quality and Outcomes;2021-04

4. Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists;CJC Open;2020-11

5. Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome;Heart and Vessels;2017-12-29